title: Epigenetics in Kidney Transplantation: Current Evidence, Predictions, and Future Research Directions.
abstract: Epigenetic modifications are changes to the genome that occur without any alteration in DNA sequence. These changes include cytosine methylation of DNA at cytosine-phosphate diester-guanine dinucleotides, histone modifications, microRNA interactions, and chromatin remodeling complexes. Epigenetic modifications may exert their effect independently or complementary to genetic variants and have the potential to modify gene expression. These modifications are dynamic, potentially heritable, and can be induced by environmental stimuli or drugs. There is emerging evidence that epigenetics play an important role in health and disease. However, the impact of epigenetic modifications on the outcomes of kidney transplantation is currently poorly understood and deserves further exploration. Kidney transplantation is the best treatment option for end-stage renal disease, but allograft loss remains a significant challenge that leads to increased morbidity and return to dialysis. Epigenetic modifications may influence the activation, proliferation, and differentiation of the immune cells, and therefore may have a critical role in the host immune response to the allograft and its outcome. The epigenome of the donor may also impact kidney graft survival, especially those epigenetic modifications associated with early transplant stressors (e.g., cold ischemia time) and donor aging. In the present review, we discuss evidence supporting the role of epigenetic modifications in ischemia-reperfusion injury, host immune response to the graft, and graft response to injury as potential new tools for the diagnosis and prediction of graft function, and new therapeutic targets for improving outcomes of kidney transplantation.
authors.affiliation: 1 Translational Genomics Transplant Laboratory, Division of Transplant, Department of Surgery, University of Virginia, Charlottesville, VA. 2 Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, VA. 3 Transplant Surgery, Division of Transplant, Department of Surgery, University of Virginia, Charlottesville, VA.
authors.forename: Valeria R
authors.initials: VR
authors.lastname: Mas
authors.forename: Thu H
authors.initials: TH
authors.lastname: Le
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Maluf
mesh_terms: D064591:Allografts; D000818:Animals; D042002:Chromatin Assembly and Disassembly; D019175:DNA Methylation; D044127:Epigenesis, Genetic; D005355:Fibrosis; D005786:Gene Expression Regulation; D020022:Genetic Predisposition to Disease; D006084:Graft Rejection / Q000235:genetics* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006085:Graft Survival / Q000235:genetics*; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D015427:Reperfusion Injury / Q000235:genetics* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D035683:MicroRNAs; D006655:Histone Deacetylases